EUCTR2004-004849-18-BE进行中（未招募）不适用
Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent obtained before undergoing any study-related activities
- •- Males or females = 18 to < 70 years of age.
- •- Newly diagnosed, histologically proven supratentorial GB (WHO Grade IV). The histological diagnosis can be obtained either from a brain biopsy or from a neurosurgical resection of the tumor.
- •- Interval of = 3 weeks but = 5 weeks since surgery or biopsy before enrollment.
- •- For subjects who had undergone a tumor biopsy, disease evaluated by Gd-MRI within 1 week prior to the first dose of cilengitide.
- •- For subjects who had undergone tumor resection or debulking, availability of a postoperative Gd-MRI performed within < 48 hours after surgery. (In the exceptional case that it was not possible to obtain a Gd-MRI within 48 hours post surgery, and upon receiving confirmation from the central registration desk, a Gd-MRI is to be performed within 1 week prior to the start of cilengitide treatment.)
- •- Tumor tissue specimens from the GB surgery (paraffin-embedded and fresh-frozen) or biopsy (paraffin-embedded and, if available, fresh frozen) must be available for central pathology review and analysis of molecular markers relevant for this study (avb3 and avb5 integrins and MGMT gene methylation status).
- •- No prior chemotherapy in the last 5 years.
- •- No prior RT of the head.
- •- Stable or decreasing dose of steroids for = 8 days.
- •- Eastern Cooperative Oncology Group performance status (ECOG PS) = 2.
- •- Women of childbearing potential must have a negative pregnancy test at screening.
- •- Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable methods of birth control, such as hormonal contraception, intra-uterine pessar (IUP) or sterilization, to avoid conception during the study and for at least 6 months after receiving the last dose of study drug.
- •- Laboratory values (within 1 week prior to the first dose of cilengitide):
- •Absolute neutrophil count =1500/mm³.
- •Platelets = 100,000/mm³.
- •Creatinine = 1.5 times upper limit of normal (ULN) or creatine clearance rate = 60 mL/min.
- •PT international normalized ratio (INR) and partial thromboplastin time (PTT) within normal limits.
- •Hemoglobin =10 mg/dL.
- •Total bilirubin = 1.5 times the ULN.
- •Aspartate aminotransferase and alanine aminotransferase = 2.5 times above ULN.
- •Alkaline phosphatase = 2.5 times above ULN.
- •- Clinically normal cardiac function without history of ischemic heart disease in the past 6 months and normal 12-lead electrocardiogram (ECG) measured during screening. No history of stroke.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Planned surgery for other diseases (e. g., dental extraction).
- •- History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment.
- •- History of prior malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for = 5 years are eligible for this study.
- •- History of coagulation disorder associated with bleeding or recurrent thrombotic events.
- •- Concurrent illness, including severe infection, which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety.
- •- Subject is pregnant, anticipates becoming pregnant within 6 months after study participation, or is currently breast-feeding.
- •- Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide.
- •- Prior antiangiogenic therapy.
- •- Placement of Gliadel® wafer at surgery.
- •- Unable to undergo Gd-MRI.
- •- Current alcohol dependence or drug abuse.
- •- Treatment with a prohibited concomitant medication (see Section 6.9.1).
- •- Known hypersensitivity to the study treatment.
- •- Legal incapacity or limited legal capacity.
- •- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before enrollment in the trial.
研究者
相似试验
进行中（未招募）
不适用
Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa studyEUCTR2004-004849-18-DEMerck KGaA50
进行中（未招募）
1 期
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study - HIT-HGG-CilMetroEUCTR2009-011898-33-DEMartin-Luther-Universität Halle-Wittenberg
进行中（未招募）
1 期
Medical treatment of patients with cancer in colon or rectumPatients with refractory colorectal cancerMedDRA version: 16.1Level: HLTClassification code 10010023Term: Colorectal neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002327-15-DKOdense University Hospital80
终止
2 期
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and AdolescentsGliomasNCT01517776Martin-Luther-Universität Halle-Wittenberg28
已完成
2 期
Multicombination Therapy of Temozolomide, Vincristine, and Interferon-beta with Radiotherapy for Malignant GliomaJPRN-UMIN000040599Department of Neurosurgery, Hirosaki University School of Medicine50